SCHEMBL329706

SCHEMBL329706

CN(C)C(=O)[C@H]1CC[C@@H](O)[C@H](N)C1

nearest known ligand 0.34

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 1/20 0.32
▸ GLI1 P08151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30128341 1.00 DPP4 (0.32) DPP4GLI1
SCHEMBL18588982 0.84 DPP4 (0.33) DPP4
SCHEMBL14504665 0.84 DPP4 (0.33) DPP4GLI1
SCHEMBL30839243 0.82 DPP4 (0.34) DPP4GLI1
SCHEMBL4760467 0.78 DPP4 (0.34) DPP4GLI1
SCHEMBL21029706 0.78 GABRR1 (0.31) —
SCHEMBL13631051 0.78 GABRR1 (0.31) —
SCHEMBL4109097 0.77 GABRR1 (0.50) —
SCHEMBL4428766 0.77 GABRR1 (0.50) —
SCHEMBL4428770 0.77 GABRR1 (0.50) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180179226-A1 Processes for the Preparation of Edoxaban and Intermediates Thereof THE BANK OF NOVA SCOTIA (CA) 2018-06-28 — — US disclosed
EP-2980067-B1 PROCESSES FOR PREPARING OPTICALLY ACTIVE DIAMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2017-05-17 — — EP disclosed
EP-2980067-B1 PROCESSES FOR PREPARING OPTICALLY ACTIVE DIAMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2017-05-17 — — EP disclosed
EP-2589590-B1 PROCESS FOR PREPARATION OF OPTICALLY ACTIVE DIAMINE DERIVATIVE SALT DAIICHI SANKYO CO LTD (JP) 2016-12-28 — — EP disclosed
US-9447118-B2 Preparation method of optically active diamine compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-09-20 — — US disclosed
US-9447118-B2 Preparation method of optically active diamine compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-09-20 — — US disclosed
US-9447118-B2 Preparation method of optically active diamine compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-09-20 — — US disclosed
EP-1925611-B1 OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME DAIICHI SANKYO CO LTD (JP) 2016-04-13 — — EP disclosed
EP-2980067-A1 PROCESSES FOR PREPARING OPTICALLY ACTIVE DIAMINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-02-03 — — EP disclosed
EP-2980067-A1 PROCESSES FOR PREPARING OPTICALLY ACTIVE DIAMINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-02-03 — — EP disclosed
US-8901345-B2 Process for preparation of optically active diamine derivative salt DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-12-02 — — US disclosed
US-20130165657-A1 PROCESS FOR PREPARATION OF OPTICALLY ACTIVE DIAMINE DERIVATIVE SALT DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-06-27 — — US disclosed
EP-2589590-A1 PROCESS FOR PREPARATION OF OPTICALLY ACTIVE DIAMINE DERIVATIVE SALT DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-05-08 — — EP disclosed
US-8357808-B2 Process for producing diamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-22 — — US disclosed
US-20120041206-A1 PROCESS FOR PRODUCING DIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-02-16 — — US disclosed
US-20120035369-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE DIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-02-09 — — US disclosed
EP-2407457-A1 PROCESS FOR PRODUCING DIAMINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2012-01-18 — — EP disclosed
EP-2407450-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE DIAMINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2012-01-18 — — EP disclosed
US-20090105491-A1 OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-04-23 — — US disclosed
EP-1925611-A1 OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME Daiichi Sankyo Company, Limited (JP) 2008-05-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105491-A1 OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME TFPI, F2, SERPINC1 DPP4 330/4885GLI1 926/4885
US-20120041206-A1 PROCESS FOR PRODUCING DIAMINE DERIVATIVE TFPI, TFPI2, DAO DPP4 919/4885GLI1 1408/4885
US-20130165657-A1 PROCESS FOR PREPARATION OF OPTICALLY ACTIVE DIAMINE DERIVATIVE SALT TFPI, F12, TFPI2 DPP4 363/4885GLI1 1241/4885
US-20120035369-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE DIAMINE DERIVATIVE F12, DAO, TFPI DPP4 2091/4885GLI1 1282/4885
US-20180179226-A1 Processes for the Preparation of Edoxaban and Intermediates Thereof VKORC1, CYP2C9, VKORC1L1 DPP4 2271/4885GLI1 3108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback